Page 7 - Five Prime News Today : Breaking News, Live Updates & Top Stories | Vimarsana

BMS strikes $350m deal to boost its immuno-oncology pipeline Will collaborate with US biotech Five Prime Therapeutics Bristol-Myers Squibb has signed a $350m deal to boost its immuno-oncology pipeline, following through on its promise last year to increase its investment in the area. The pharma company will collaborate with San Francisco-based biotech Five Prime Therapeutics to discover, develop and commercialise novel immuno-oncology therapies. BMS prioritised immuno-oncology, which involves research into how a body's own immune system can fight cancer, in November when it discontinued dis...

Share this article Share this article THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., March 4, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Five Prime Therapeutics (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies, today announced an agreement under which Amgen will acquire Five Prime Therapeutics for $38.00 per share in cash, representing an equity value of approximately $1.9 billion. This acquisition adds Five Prime's innovative pipeline to Amgen's leading oncology portfolio. (PRNewsfoto/Amgen) Five Prime's ...

The big biotech wants to bolster its late-stage pipeline with a potential new stomach cancer treatment.

<div class="at-above-post addthis_tool" data-url="https://www.metro.us/amgen-bets-on-1-9-billion/"></div>(Reuters) – Drugmaker Amgen Inc is buying Five Prime Therapeutics for about $1.9 billion to expand its line of gastric cancer drug candidates and its presence in Asia-Pacific, the companies said on Thursday. Amgen has been looking to grow in the oncology market in the region since gaining a toehold in China in 2019 through […]<!-- AddThis Advanced Settings above via filter on get_the_excerpt --><!-- AddThis Advanced Settings below via fi...

NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Five Prime Therapeutics, Inc. (NASDAQ: FPRX) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Amgen Inc. (NASDAQ: AMGN). Click here to learn more and participate in the action. On March 4, 2021, Five Prime announced that it had signed an agreement to be acquired by Amgen for approximately $1.9 billion. Pursuant to the merger...